Table 3.
Effect of inflammation-associated biomarkers on clinical phase in propensity score-matched pairs of German and Japanese patients with cardiovascular disease.
| Inflammation Biomarkers | GERMANY | JAPAN | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | Uncomplicated | Complicated | Critical | p-Value | Total | Uncomplicated | Complicated | Critical | p-Value | |
| Interleukin-6 | ||||||||||
| <1.8 | 0 | 0 (0%) | 0 (0%) | 0 (0%) | 1.0000 | 1 | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 1.0000 |
| 1.8–199 | 19 | 16 (84.21%) | 3 (15.79%) | 0 (0.0%) | 39 | 23 (58.97%) | 16 (41.03%) | 0 (0.0%) | ||
| 200–4999 | 2 | 2 (100.0%) | 0 (0.0%) | 0 (0.0%) | 1 | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | ||
| CRP | ||||||||||
| <3 | 3 | 3 (100.0%) | 0 (0.0%) | 0 (0.0%) | 1.0000 | 20 | 17 (85.0%) | 3 (15.0%) | 0 (0.0%) | 0.0780 |
| 3–29 | 0 | 0 (0%) | 0 (0%) | 0 (0%) | 40 | 24 (60.0%) | 16 (40.0%) | 0 (0.0%) | ||
| >30 | 28 | 24 (85.71%) | 3 (10.71%) | 1 (3.57%) | 0 | 0 (0%) | 0 (0%) | 0 (0%) | ||
| White blood cells | ||||||||||
| <4000 | 8 | 6 (75.0%) | 1 (12.5%) | 1 (12.5%) | 0.2444 | 16 | 13 (81.25%) | 3 (18.75%) | 0 (0.0%) | 0.2284 |
| 4000–7999 | 12 | 12 (100.0%) | 0 (0.0%) | 0 (0.0%) | 36 | 24 (66.67%) | 12 (33.33%) | 0 (0.0%) | ||
| >8000 | 8 | 7 (87.5%) | 1 (12.5%) | 0 (0.0%) | 8 | 4 (50.0%) | 4 (50.0%) | 0 (0.0%) | ||
| Neutrophil | ||||||||||
| <2000 | 2 | 2 (100.0%) | 0 (0.0%) | 0 (0.0%) | 1.0000 | 5 | 3 (60.0%) | 2 (40.0%) | 0 (0.0%) | 1.0000 |
| 2000–8999 | 21 | 19 (90.48%) | 2 (9.52%) | 0 (0.0%) | 39 | 23 (58.97%) | 16 (41.03%) | 0 (0.0%) | ||
| ≥9000 | 2 | 2 (100.0%) | 0 (0.0%) | 0 (0.0%) | 2 | 1 (50.0%) | 1 (50.0%) | 0 (0.0%) | ||
Data are n (%). p-values were obtained by comparing the values of a biomarker within each country separately, considering the clinical phase at diagnosis. p values were calculated by X2 or Fischer’s exact test.